Talphera, Inc. filings document the regulatory record for a Nasdaq-listed specialty pharmaceutical company focused on medically supervised therapies. Recent Form 8-K reports cover financial results, corporate updates, private placements of common stock and pre-funded warrants, board appointments, equity-plan matters and Nasdaq listing-compliance notices.
The company’s proxy materials describe stockholder voting matters, director elections, executive compensation, equity awards and employee stock plan approvals. Talphera’s filings also identify its Delaware incorporation, Nasdaq Capital Market listing, registered common stock and capital-structure disclosures relevant to its pharmaceutical development business.
Talphera, Inc. filed Amendment No. 2 to a Schedule 13G/A reporting that Laurence W. Lytton and the Lytton-Kambara Foundation each beneficially own 1,246,444 shares of Common Stock. The filing states this equals 2.5% of the class, calculated from 50,049,824 shares outstanding as of March 18, 2026.
The report breaks out voting and dispositive power as 0 sole and 1,246,444 shared for both reporting persons and includes an agreement regarding a joint filing as Exhibit 99.1.
Talphera, Inc. reports a Q1 2026 net loss of $2.6 million, similar to the prior-year period, as it continues investing in Niyad, its nafamostat-based anticoagulant for dialysis circuits. Research and development expenses rose to $1.7 million and selling, general and administrative costs to $2.3 million, reflecting higher trial activity and corporate spending.
Cash, cash equivalents and short-term investments totaled $21.1 million as of March 31, 2026, slightly above year-end, helped by $4.1 million of gross proceeds from a private placement of common stock and pre-funded warrants. The company discloses “substantial doubt” about its ability to continue as a going concern and expects to need additional capital within 12 months to fund operations.
Talphera’s NEPHRO CRRT registrational trial for Niyad is ongoing, with completion expected in 2026. The FDA has granted Niyad Breakthrough Device Designation, but Niyad and related nafamostat programs remain pre-revenue. Talphera also notes a Nasdaq notice for failing to maintain the $1.00 minimum bid price requirement, which does not immediately affect its listing but adds execution risk around future financing and shareholder value.
Talphera, Inc. reported first quarter 2026 results, highlighting continued progress in its NEPHRO CRRT Phase 3 study of Niyad, a nafamostat-based anticoagulant for Continuous Renal Replacement Therapy in intensive care settings.
For the three months ended March 31, 2026, revenue was $0 compared with $27,000 a year earlier, while operating expenses rose to $3.9 million from $2.9 million, reflecting higher research and development and selling, general and administrative costs. A $1.2 million gain from the change in fair value of warrant liability and higher interest income helped reduce the net loss to $2.6 million from $2.6 million in the prior-year period, with basic and diluted net loss per share improving to $0.04 from $0.10 as the share count increased.
Cash, cash equivalents and investments totaled $21.1 million as of March 31, 2026, slightly above $20.4 million at year-end 2025, supporting ongoing clinical development. Talphera reaffirmed its expectation that the NEPHRO CRRT study will complete later in 2026 and emphasized the potential for nafamostat to address an unmet need as a regional anticoagulant alternative to heparin and citrate in CRRT.
TALPHERA, INC. Schedule 13G/A reports that Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon each disclose beneficial ownership of 12,925,597 shares representing 9.9% of common stock based on 51,899,648 ordinary shares outstanding as of April 24, 2026.
The filing states that the reported totals include 3,353,916 shares held, 2,941,180 shares issuable upon exercise of warrants and 6,630,501 shares issuable upon exercise of pre-funded warrants, and it notes these convertible instruments are subject to a blocker provision that prevents exercises that would result in beneficial ownership above 9.99%.
Talphera, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on June 22, 2026. The agenda includes electing three directors, ratifying BPM LLP as independent auditor for the year ending December 31, 2026, and an advisory “say-on-pay” vote on executive compensation.
Stockholders are also asked to approve an amended 2020 Equity Incentive Plan that adds 4,000,000 shares to the share pool and an amended 2011 Employee Stock Purchase Plan increasing its reserve to 545,000 shares. Only holders of 51,899,648 common shares outstanding as of April 24, 2026 may vote, one vote per share.
TALPHERA, INC. CEO Vincent J. Angotti reported a routine tax-related share disposition. On April 2, 2026, he surrendered 9,938 shares of common stock at $0.7223 per share to the company to cover required tax withholdings from vesting RSUs. After this transaction, he directly holds 790,767 shares of TALPHERA common stock.
TALPHERA, INC. Chief Financial Officer Raffi Asadorian reported a routine share disposition related to taxes. On the RSU vesting date, 2,444 shares of common stock were surrendered back to the company at $0.7223 per share to cover required tax withholdings, rather than being sold on the open market. Following this tax-withholding transaction, the CFO directly holds 85,879 shares of Talphera common stock.
TALPHERA, INC. Chief Medical Officer Aslam Shakil reported a tax-withholding share disposition related to vesting restricted stock units. On this Form 4, 2,118 shares of common stock were surrendered back to the company at an effective price of $0.7223 per share to cover required tax withholdings. After this transaction, Shakil directly holds 81,060 shares of TALPHERA common stock. The filing records a compensation-related tax event rather than an open-market purchase or sale.
TALPHERA, INC. Chief Engineering Officer Badri N. Dasu reported a routine tax-related share disposition. On the RSU vesting date, 2,444 shares of common stock were surrendered back to the company at an implied price of $0.7223 per share to cover required tax withholdings, rather than being sold on the open market. After this withholding transaction, Dasu directly holds 71,440 shares of TALPHERA common stock.